SCHEDULE 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

DEFA14A - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

DEF 14A - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

SCHEDULE 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

10-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

10-Q - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the "Investor

64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK + rituximab not yet reached and is at least 19.4 months, in line with approved auto-CAR-T therapies in aggressive B-NHL AlloNK's activity and well-tolerated safety profile in aggressive B-NHL patients support the potential to deliver deep B-cell depletion in a refractory autoimmune population in outpatient community settings SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose

IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cel

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial

SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

SC 13D - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)